Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05096143 · ClinicalTrials.gov registry record
A Cohort Study to Compare the Hospitalization Between Naive Sacubitril/Valsartan and Naive ACEi/ARBs Heart Failure Patients With Reduced Ejection Fraction Using Secondary US Electronic Health Records Data
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 42,269
- Enrollment target
NCT05096143: Completed study, sponsored by Novartis Pharmaceuticals.
NCT05096143 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 42,269 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05096143 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 42,269 participants
- Enrollment target
Study Summary
A non-interventional retrospective cohort study conducted to compare the naive sacubitril/valsartan Heart Failure with reduced Ejection Fraction (HFrEF) patient population to a matched naive ACEi/ARB HFrEF patient population.
Primary Outcome
Heart failure hospitalizations were defined by ICD-9-CM (The International Classification of Diseases, 9th Revision, Clinical Modification) and ICD-10-CM (International Classification of Diseases, 10th Revision, Clinical Modifier) codes for HF listed within the primary diagnoses associated with a hospitalization that occurred during the follow-up period.
Interventions
- DRUG Sacubitril/valsartan
- DRUG ACEi/ARB
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42,269 participants |
| Start Date | 2020-06-03 |
| Est. Completion | 2020-10-19 |
What the finished NCT05096143 record still lists
NCT05096143 is an observational study that tracks outcomes without assigning an intervention. Its 42,269 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Sacubitril/valsartan is the first listed.
NCT05096143 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05096143 about?
NCT05096143 is a clinical study titled "A Cohort Study to Compare the Hospitalization Between Naive Sacubitril/Valsartan and Naive ACEi/ARBs Heart Failure Patients With Reduced Ejection Fraction Using Secondary US Electronic Health Records Data". A non-interventional retrospective cohort study conducted to compare the naive sacubitril/valsartan Heart Failure with reduced Ejection Fraction (HFrEF) patient population to a matched naive ACEi/ARB HFrEF patient population.
What is the current status of trial NCT05096143?
This trial is currently completed. The enrollment target is 42,269 participants. The study started on 2020-06-03. Estimated completion is 2020-10-19.
What interventions are being tested in trial NCT05096143?
The interventions under investigation include: Sacubitril/valsartan (DRUG), ACEi/ARB (DRUG).
Who is sponsoring clinical trial NCT05096143?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01255748 · 40,000 participants
Registry Study for Radiation Therapy Outcomes
- NCT04994756 · 40,000 participants
Stroke Thrombectomy and Aneurysm Registry
- NCT06768814 · 40,000 participants · NA
Overdose Recovery and Care Access (ORCA) Qualitative Stakeholder Interviews and County-level Data
- NCT07109427 · 40,000 participants · NA
Impact of an Electronic Health Record Maintenance Alert on PSA Screening Rates in a 10-Hospital Integrated Health System
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI